findmyKOL
Clinical trialNCT02072486CompletedInterventional

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

SponsorRoswell Park Cancer InstituteEnrollment30Advanced Adult Hepatocellular CarcinomaLocalized Non-Resectable Adult Hepatocellular CarcinomaStage III Childhood Hepatocellular CarcinomaStage IIIA Hepatocellular CarcinomaStage IIIB Hepatocellular CarcinomaStage IIIC Hepatocellular Carcinoma+3 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Roswell Park Cancer Institute

    Buffalo, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Nov 2013
Primary completion
19 Jul 2019
Completion
19 Jul 2020
Last update posted
25 Jul 2022
Registered enrollment
30
Registry id
NCT02072486

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.